Literature DB >> 680585

Long-term follow-up of chronic active hepatitis of moderate severity.

J De Groote, J Fevery, L Lepoutre.   

Abstract

A group of patients with only moderately active chronic hepatitis has been studied. The follow-up was long (mean 87 months). All patients except one were treated with prednisone and/or azathioprine. Of the hepatitis B virus positive patients two-thirds developed cirrhosis between the second and fifth year of evolution, while in the hepatitis B negative group this occurred in less than one-third. The transition to cirrhosis was clinically silent. The patients were all allowed to do their normal work except in the terminal stages of cirrhosis. Five patients died of causes related to the disease: three patients with cirrhosis and hepatocellular carcinoma, one with gallbladder carcinoma, and one from bleeding varices. The high incidence of tumour, especially liver-cell carcinoma, may be due to a cumulative effect of the presence of hepatitis B virus, cirrhotic transformation, and immuno-suppression. The other patients are currently in apparently good health.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 680585      PMCID: PMC1412017          DOI: 10.1136/gut.19.6.510

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

1.  The immunology of acute and chronic hepatitis.

Authors:  R Wright; S Rassam
Journal:  Clin Gastroenterol       Date:  1976-05

2.  [Hepatitis-B-antigen in chronic liver diseases (author's transl)].

Authors:  H Henning; I Tripatzis; H H von Braun; C J Lüders
Journal:  Med Klin       Date:  1973-11-16

3.  Detection of hepatitis-B antigen by radioimmunoassay in chronic liver disease and hepatocellular carcinoma in Great Britain.

Authors:  W D Reed; R B Stern; A L Eddleston; R Williams; A J Zuckerman; A Bowes; P M Earl
Journal:  Lancet       Date:  1973-09-29       Impact factor: 79.321

4.  Chronic active hepatitis in children.

Authors:  R S Dubois; A Silverman; T L Slovis
Journal:  Am J Dig Dis       Date:  1972-07

5.  Primary hepatoma in Uganda. A prospective clinical and epidemiologic study of forty-six patients.

Authors:  M E Alpert; M S Hutt; C S Davidson
Journal:  Am J Med       Date:  1969-05       Impact factor: 4.965

6.  Hepatitis-associated antigen in chronic liver disease.

Authors:  S J Hadziyannis; G E Merikas; A P Afroudakis
Journal:  Lancet       Date:  1970-07-11       Impact factor: 79.321

7.  A classification of chronic hepatitis.

Authors:  J De Groote; V J Desmet; P Gedigk; G Korb; H Popper; H Poulsen; P J Scheuer; M Schmid; H Thaler; E Uehlinger
Journal:  Lancet       Date:  1968-09-14       Impact factor: 79.321

8.  Hepatitis-associated antigen in chronic liver disease.

Authors:  R A Fox; S P Niazi; S Sherlock
Journal:  Lancet       Date:  1969-09-20       Impact factor: 79.321

9.  Australia antigen in acute and chronic liver disease.

Authors:  R Wright; R W McCollum; G Klatskin
Journal:  Lancet       Date:  1969-07-19       Impact factor: 79.321

10.  Protracted and recurrent forms of viral hepatitis.

Authors:  F G Wewalka
Journal:  Am J Dis Child       Date:  1972-04
View more
  26 in total

1.  Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.

Authors:  Hui-Fang Hung; Hsiu-Hsi Chen
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

2.  Effects of interferon-alpha therapy on serum and liver HBV DNA in patients with chronic hepatitis B.

Authors:  S V Feinman; B Berris; R Sooknanan; B Fernandes; S Bojarski
Journal:  Dig Dis Sci       Date:  1992-10       Impact factor: 3.199

3.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

4.  Antiviral treatment in chronic infection with hepatitis B virus.

Authors:  G Alexander; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-05

Review 5.  Natural history of the HBsAg carrier.

Authors:  M G Anderson; I M Murray-Lyon
Journal:  Gut       Date:  1985-08       Impact factor: 23.059

6.  Prognostic significance of bridging necrosis in chronic active hepatitis.

Authors:  T Okuno; T Okanoue; T Takino; K Mori
Journal:  Gastroenterol Jpn       Date:  1983-12

7.  Hepatitis B surface antigen circulating immune complexes (HBsAg-CICs) in patients with hepatitis B and asymptomatic HBsAg carriers.

Authors:  N Anh-Tuan; E Novák
Journal:  Clin Exp Immunol       Date:  1981-02       Impact factor: 4.330

8.  Influence of (+)-cyanidanol-3 on the leukocyte migration inhibition test carried out in the presence of purified protein derivative and hepatitis B surface antigen.

Authors:  J J Vallotton; P C Frei
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

Review 9.  Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Authors:  Albert J Czaja; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

10.  A study on the relationship between the prognosis of chronic active hepatitis and the HBV associated antigen/antibody systems.

Authors:  Y Kosaka; Y Tameda; Y Okuda; K Takase; H Sawa; H Takezawa
Journal:  Gastroenterol Jpn       Date:  1981-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.